The immunogenicity and safety of intradermal hepatitis B vaccine

William Toffler, J. S. Olenick, N. E. Wolf, Z. H. Retzlaff, J. R. Swanson, T. A. Kenny

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. One of the chief barriers to a greater use of hepatitis B vaccine is the high cost of the vaccine itself. A number of small research trials have shown that an adequate immune response can be induced at a much lower cost by administering one tenth of the vaccine using an intradermal technique. The purpose of this study was to ascertain whether these results could be replicated in a larger clinical trial. Methods. Vaccine recipients included health care providers, police officers, and firefighters. Recipients were given 0.1 mL of plasma-derived hepatitis B vaccine intradermally on days 1, 30, and 180. Antibody response was measured on day 210, with seroconversion defined as a sample-to-negative (S/N) ratio of greater than or equal to 10. Any local and systemic side effects were documented. Results. Six hundred sixteen individuals completed the vaccination series, and seroconversion occurred in 534 (86.7%). The rate of seroconversion in those younger than 40 years was 91.2% and in those 40 years and older was 75.1%. The mean S/N ratio was 154.9 (range 0 to 620) and decreased with increasing age (r = -.25, P = .0001). Side effects were largely limited to local reactions. Conclusions. The results support the use of the intradermal technique as a cost-effective alternative to the intramuscular route in individuals younger than 40 years. The intradermal technique may be used in older individuals if titers are obtained to assure seroconversion. Because of the restricted availability of the plasma-derived vaccine used in this study, similar trials with recombinant vaccine should be undertaken.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalJournal of Family Practice
Volume33
Issue number2
StatePublished - 1991

Fingerprint

Hepatitis B Vaccines
Vaccines
Safety
Costs and Cost Analysis
Firefighters
Synthetic Vaccines
Police
Health Personnel
Antibody Formation
Vaccination
Clinical Trials
Seroconversion
Research

Keywords

  • cost control
  • injections, subcutaneous
  • Viral hepatitis vaccines

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Toffler, W., Olenick, J. S., Wolf, N. E., Retzlaff, Z. H., Swanson, J. R., & Kenny, T. A. (1991). The immunogenicity and safety of intradermal hepatitis B vaccine. Journal of Family Practice, 33(2), 149-154.

The immunogenicity and safety of intradermal hepatitis B vaccine. / Toffler, William; Olenick, J. S.; Wolf, N. E.; Retzlaff, Z. H.; Swanson, J. R.; Kenny, T. A.

In: Journal of Family Practice, Vol. 33, No. 2, 1991, p. 149-154.

Research output: Contribution to journalArticle

Toffler, W, Olenick, JS, Wolf, NE, Retzlaff, ZH, Swanson, JR & Kenny, TA 1991, 'The immunogenicity and safety of intradermal hepatitis B vaccine', Journal of Family Practice, vol. 33, no. 2, pp. 149-154.
Toffler W, Olenick JS, Wolf NE, Retzlaff ZH, Swanson JR, Kenny TA. The immunogenicity and safety of intradermal hepatitis B vaccine. Journal of Family Practice. 1991;33(2):149-154.
Toffler, William ; Olenick, J. S. ; Wolf, N. E. ; Retzlaff, Z. H. ; Swanson, J. R. ; Kenny, T. A. / The immunogenicity and safety of intradermal hepatitis B vaccine. In: Journal of Family Practice. 1991 ; Vol. 33, No. 2. pp. 149-154.
@article{5fb50d09b94044f3b87b1734eae04509,
title = "The immunogenicity and safety of intradermal hepatitis B vaccine",
abstract = "Background. One of the chief barriers to a greater use of hepatitis B vaccine is the high cost of the vaccine itself. A number of small research trials have shown that an adequate immune response can be induced at a much lower cost by administering one tenth of the vaccine using an intradermal technique. The purpose of this study was to ascertain whether these results could be replicated in a larger clinical trial. Methods. Vaccine recipients included health care providers, police officers, and firefighters. Recipients were given 0.1 mL of plasma-derived hepatitis B vaccine intradermally on days 1, 30, and 180. Antibody response was measured on day 210, with seroconversion defined as a sample-to-negative (S/N) ratio of greater than or equal to 10. Any local and systemic side effects were documented. Results. Six hundred sixteen individuals completed the vaccination series, and seroconversion occurred in 534 (86.7{\%}). The rate of seroconversion in those younger than 40 years was 91.2{\%} and in those 40 years and older was 75.1{\%}. The mean S/N ratio was 154.9 (range 0 to 620) and decreased with increasing age (r = -.25, P = .0001). Side effects were largely limited to local reactions. Conclusions. The results support the use of the intradermal technique as a cost-effective alternative to the intramuscular route in individuals younger than 40 years. The intradermal technique may be used in older individuals if titers are obtained to assure seroconversion. Because of the restricted availability of the plasma-derived vaccine used in this study, similar trials with recombinant vaccine should be undertaken.",
keywords = "cost control, injections, subcutaneous, Viral hepatitis vaccines",
author = "William Toffler and Olenick, {J. S.} and Wolf, {N. E.} and Retzlaff, {Z. H.} and Swanson, {J. R.} and Kenny, {T. A.}",
year = "1991",
language = "English (US)",
volume = "33",
pages = "149--154",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "2",

}

TY - JOUR

T1 - The immunogenicity and safety of intradermal hepatitis B vaccine

AU - Toffler, William

AU - Olenick, J. S.

AU - Wolf, N. E.

AU - Retzlaff, Z. H.

AU - Swanson, J. R.

AU - Kenny, T. A.

PY - 1991

Y1 - 1991

N2 - Background. One of the chief barriers to a greater use of hepatitis B vaccine is the high cost of the vaccine itself. A number of small research trials have shown that an adequate immune response can be induced at a much lower cost by administering one tenth of the vaccine using an intradermal technique. The purpose of this study was to ascertain whether these results could be replicated in a larger clinical trial. Methods. Vaccine recipients included health care providers, police officers, and firefighters. Recipients were given 0.1 mL of plasma-derived hepatitis B vaccine intradermally on days 1, 30, and 180. Antibody response was measured on day 210, with seroconversion defined as a sample-to-negative (S/N) ratio of greater than or equal to 10. Any local and systemic side effects were documented. Results. Six hundred sixteen individuals completed the vaccination series, and seroconversion occurred in 534 (86.7%). The rate of seroconversion in those younger than 40 years was 91.2% and in those 40 years and older was 75.1%. The mean S/N ratio was 154.9 (range 0 to 620) and decreased with increasing age (r = -.25, P = .0001). Side effects were largely limited to local reactions. Conclusions. The results support the use of the intradermal technique as a cost-effective alternative to the intramuscular route in individuals younger than 40 years. The intradermal technique may be used in older individuals if titers are obtained to assure seroconversion. Because of the restricted availability of the plasma-derived vaccine used in this study, similar trials with recombinant vaccine should be undertaken.

AB - Background. One of the chief barriers to a greater use of hepatitis B vaccine is the high cost of the vaccine itself. A number of small research trials have shown that an adequate immune response can be induced at a much lower cost by administering one tenth of the vaccine using an intradermal technique. The purpose of this study was to ascertain whether these results could be replicated in a larger clinical trial. Methods. Vaccine recipients included health care providers, police officers, and firefighters. Recipients were given 0.1 mL of plasma-derived hepatitis B vaccine intradermally on days 1, 30, and 180. Antibody response was measured on day 210, with seroconversion defined as a sample-to-negative (S/N) ratio of greater than or equal to 10. Any local and systemic side effects were documented. Results. Six hundred sixteen individuals completed the vaccination series, and seroconversion occurred in 534 (86.7%). The rate of seroconversion in those younger than 40 years was 91.2% and in those 40 years and older was 75.1%. The mean S/N ratio was 154.9 (range 0 to 620) and decreased with increasing age (r = -.25, P = .0001). Side effects were largely limited to local reactions. Conclusions. The results support the use of the intradermal technique as a cost-effective alternative to the intramuscular route in individuals younger than 40 years. The intradermal technique may be used in older individuals if titers are obtained to assure seroconversion. Because of the restricted availability of the plasma-derived vaccine used in this study, similar trials with recombinant vaccine should be undertaken.

KW - cost control

KW - injections, subcutaneous

KW - Viral hepatitis vaccines

UR - http://www.scopus.com/inward/record.url?scp=0025942036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025942036&partnerID=8YFLogxK

M3 - Article

C2 - 1832438

AN - SCOPUS:0025942036

VL - 33

SP - 149

EP - 154

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 2

ER -